These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38993658)

  • 1. Therapeutic Potential of Naltrexone in the Niche of Psychopharmacology.
    Naguy A; Alamiri B
    Psychopharmacol Bull; 2024 Jul; 54(3):97-99. PubMed ID: 38993658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
    Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
    Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
    Hartung DM; McCarty D; Fu R; Wiest K; Chalk M; Gastfriend DR
    J Subst Abuse Treat; 2014 Aug; 47(2):113-21. PubMed ID: 24854219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
    Goonoo N; Bhaw-Luximon A; Ujoodha R; Jhugroo A; Hulse GK; Jhurry D
    J Control Release; 2014 Jun; 183():154-66. PubMed ID: 24704710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone in the treatment of opioid-dependent pregnant women: common ground.
    Jones HE; Chisolm MS; Jansson LM; Terplan M
    Addiction; 2013 Feb; 108(2):255-6. PubMed ID: 23331881
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.
    Shi Z; Wang AL; Jagannathan K; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
    J Psychiatry Neurosci; 2018 Jul; 43(4):254-261. PubMed ID: 29947607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
    DeFulio A; Everly JJ; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Drug Alcohol Depend; 2012 Jan; 120(1-3):48-54. PubMed ID: 21782353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular extended-release naltrexone: current evidence.
    Gastfriend DR
    Ann N Y Acad Sci; 2011 Jan; 1216():144-66. PubMed ID: 21272018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
    Lobmaier PP; Kunøe N; Gossop M; Waal H
    CNS Neurosci Ther; 2011 Dec; 17(6):629-36. PubMed ID: 21554565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naltrexone: Not Just for Opioids Anymore.
    Sudakin D
    J Med Toxicol; 2016 Mar; 12(1):71-5. PubMed ID: 26546222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
    Spanagel R; Zieglgänsberger W
    Trends Pharmacol Sci; 1997 Feb; 18(2):54-9. PubMed ID: 9090311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.
    Vagenas P; Di Paola A; Herme M; Lincoln T; Skiest DJ; Altice FL; Springer SA
    J Subst Abuse Treat; 2014 Jul; 47(1):35-40. PubMed ID: 24674234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
    Malone M; McDonald R; Vittitow A; Chen J; Obi R; Schatz D; Tofighi B; Garment A; Kermack A; Goldfeld K; Gold H; Laska E; Rotrosen J; Lee JD
    Contemp Clin Trials; 2019 Jun; 81():102-109. PubMed ID: 30986535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.
    Brünen S; Bekier NK; Hiemke C; Korf F; Wiedemann K; Jahn H; Kiefer F
    Alcohol Alcohol; 2019 Jan; 54(1):51-55. PubMed ID: 30260366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone in alcohol dependence.
    Hartmann PM
    Am Fam Physician; 1997 Apr; 55(5):1877-9, 1883-4. PubMed ID: 9105212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial.
    Collins SE; Saxon AJ; Duncan MH; Smart BF; Merrill JO; Malone DK; Jackson TR; Clifasefi SL; Joesch J; Ries RK
    Contemp Clin Trials; 2014 Jul; 38(2):221-34. PubMed ID: 24846619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opiate antagonists in children and adolescents.
    Chabane N; Leboyer M; Mouren-Simeoni MC
    Eur Child Adolesc Psychiatry; 2000; 9 Suppl 1():I44-50. PubMed ID: 11140779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
    Haile CN; Kosten TA; Kosten TR
    Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial.
    Jarvis BP; Holtyn AF; DeFulio A; Koffarnus MN; Leoutsakos JS; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Drug Alcohol Depend; 2019 Apr; 197():220-227. PubMed ID: 30852374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.